PALO ALTO, Calif.--(BUSINESS WIRE)--Neuvivo, a late-clinical stage biopharmaceutical company, today announced promising results from two groundbreaking publications on its investigational ...
Subset analysis of patients whose ALS did not progress from a long-term survival study showed NP001 saved lung function and extended life by 22 months vs. a control group (~70% on riluzole) NP001 ...
In a previous analysis of this phase 3 trial, first-line ribociclib plus letrozole resulted in significantly longer progression-free survival than letrozole alone among postmenopausal patients with ...
The human body wasn’t designed to handle the relentless stress of modern life, yet millions of people are unknowingly trapped in a state of chronic physiological arousal that’s wreaking havoc on their ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback